P. Ang

发表

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.

H. Gómez, D. Doval, M. A. Chavez, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients

P. Ang, Y. Cheung, C. Khor, 2016, Clinical Pharmacokinetics.

Development of a next-generation sequencing method for BRCA mutation screening: a comparison between a high-throughput and a benchtop platform.

Puay Hoon Tan, Zhen Xuan Yeo, P. Tan, 2012, The Journal of molecular diagnostics : JMD.

Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.

P. Ang, Y. Cheung, Y. Yap, 2016, British journal of clinical pharmacology.

Identification of Novel Breast Cancer Risk Loci.

P. Ang, P. Munusamy, M. Tan, 2017, Cancer research.

Breast-cancer risk in families with mutations in PALB2.

P. Ang, Peter Ang, Ann S G Lee, 2014, The New England journal of medicine.

Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients

P. Ang, B. Chowbay, E. Sandanaraj, 2008, Cancer science.

Phase II, open label study of SB-715992 (Ispinesib) in subjects with advanced or metastatic breast cancer

M. Piccart, P. Ang, A. Wardley, 2005 .

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens

Sung-Bae Kim, W. Gradishar, R. Bose, 2021, Breast Cancer Research and Treatment.

Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients

P. Ang, B. Chowbay, N. Wong, 2016, The Pharmacogenomics Journal.

Whole-exome sequencing of BRCA-negative breast cancer patients and case–control analyses identify variants associated with breast cancer susceptibility

P. Ang, Melissa Hum, M. Tan, 2022, Human Genomics.

CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients

P. Ang, B. Chowbay, N. Wong, 2008, Cancer science.

Genetic susceptibility for breast cancer--risk assessment and counseling.

P. Ang, J. Garber, 2001, Seminars in oncology.

Assessment of PARP4 as a candidate breast cancer susceptibility gene

P. Ang, P. Munusamy, M. Tan, 2019, Breast Cancer Research and Treatment.

Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore

P. Ang, M. Tan, S. Rozen, 2016, npj Genomic Medicine.

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.

Julie O. Culver, F. Couch, E. Goode, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRCA1 and BRCA2 Mutations in an Asian Clinic-based Population Detected Using a Comprehensive Strategy

I. H. Lim, P. Tan, P. Ang, 2007, Cancer Epidemiology Biomarkers & Prevention.

Evaluation of three polygenic risk score models for the prediction of breast cancer risk in Singapore Chinese

P. Tan, P. Ang, P. Munusamy, 2018, Oncotarget.

Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens

P. Ang, K. Rau, M. Hou, 2021, Breast Cancer Research and Treatment.

Evaluation of nanofluidics technology for high-throughput SNP genotyping in a clinical setting.

P. Ang, Y. Yap, G. Ho, 2011, The Journal of molecular diagnostics : JMD.

Detection of a novel Alu‐mediated BRCA1 exon 13 duplication in Chinese breast cancer patients and implications for genetic testing

P. Ang, Asg Lee, As Lee, 2006, Clinical genetics.

Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population

P. Tan, P. Ang, M. Tan, 2015, PloS one.

Cross‐Ancestry Genome‐Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations

H. Brauch, P. Ang, Yitian Zhou, 2023, Clinical pharmacology and therapeutics.

Association of common genetic variants with breast cancer risk and clinicopathological characteristics in a Chinese population

P. Ang, Y. Yap, G. Ho, 2012, Breast Cancer Research and Treatment.

Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors.

P. Ang, E. Tan, S. Hee, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Improving Indel Detection Specificity of the Ion Torrent PGM Benchtop Sequencer

Zhen Xuan Yeo, Z. Yeo, P. Ang, 2012, PloS one.

Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients.

Balram Chowbay, P. Ang, B. Chowbay, 2007, Pharmacogenomics.

Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women

Kee Seng Chia, Puay Hoon Tan, P. Tan, 2012, Breast Cancer Research.

CHEK2*1100delC screening of Asian women with a family history of breast cancer is unwarranted.

P. Ang, A. Lee, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women

P. Tan, P. Ang, K. Chia, 2012, Breast Cancer Research.

PXR Pharmacogenetics: Association of Haplotypes with Hepatic CYP3A4 and ABCB1 Messenger RNA Expression and Doxorubicin Clearance in Asian Breast Cancer Patients

P. Ang, B. Chowbay, N. Wong, 2008, Clinical Cancer Research.

Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination chemotherapy

P. Ang, Y. Yap, N. Wong, 2007 .

Identification of Novel Breast Cancer Risk Loci.

P. Ang, P. Munusamy, M. Tan, 2017, Cancer research.

Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer.

P. Ang, B. Chowbay, N. Wong, 2008, Breast.